An untapped window of opportunity for glioma: targeting therapy-induced senescence prior to recurrence

Cecile Riviere-Cazaux, Lucas P. Carlstrom, Bryan J. Neth, Ian E. Olson, Karishma Rajani, Masum Rahman, Samar Ikram, Moustafa A. Mansour, Bipasha Mukherjee, Arthur E. Warrington, Susan C. Short, Thomas von Zglinicki, Desmond A. Brown, Sandeep Burma, Tamar Tchkonia, Marissa J. Schafer, Darren J. Baker, Sani H. Kizilbash, James L. Kirkland, Terry C. Burns

Producción científica: Review articlerevisión exhaustiva

1 Cita (Scopus)

Resumen

High-grade gliomas are primary brain tumors that are incredibly refractory long-term to surgery and chemoradiation, with no proven durable salvage therapies for patients that have failed conventional treatments. Post-treatment, the latent glioma and its microenvironment are characterized by a senescent-like state of mitotic arrest and a senescence-associated secretory phenotype (SASP) induced by prior chemoradiation. Although senescence was once thought to be irreversible, recent evidence has demonstrated that cells may escape this state and re-enter the cell cycle, contributing to tumor recurrence. Moreover, senescent tumor cells could spur the growth of their non-senescent counterparts, thereby accelerating recurrence. In this review, we highlight emerging evidence supporting the use of senolytic agents to ablate latent, senescent-like cells that could contribute to tumor recurrence. We also discuss how senescent cell clearance can decrease the SASP within the tumor microenvironment thereby reducing tumor aggressiveness at recurrence. Finally, senolytics could improve the long-term sequelae of prior therapy on cognition and bone marrow function. We critically review the senolytic drugs currently under preclinical and clinical investigation and the potential challenges that may be associated with deploying senolytics against latent glioma. In conclusion, senescence in glioma and the microenvironment are critical and potential targets for delaying or preventing tumor recurrence and improving patient functional outcomes through senotherapeutics.

Idioma originalEnglish (US)
Número de artículo126
Publicaciónnpj Precision Oncology
Volumen7
N.º1
DOI
EstadoPublished - dic 2023

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Huella

Profundice en los temas de investigación de 'An untapped window of opportunity for glioma: targeting therapy-induced senescence prior to recurrence'. En conjunto forman una huella única.

Citar esto